Search tips
Search criteria 


Logo of brjcancerBJC HomepageBJC Advance online publicationBJC Current IssueSubmitting an article to BJCWeb feeds
Br J Cancer. 1999 August; 80(12): 1968–1973.
PMCID: PMC2363143

Somatic mutations in the p53 gene and prognosis in breast cancer: a meta-analysis


Many studies have investigated the association between alterations in the p53 gene and clinical outcome of breast cancer, and most investigators have reported poorer overall and disease-free survival (as indicated by a relative hazard (RH) greater than one) in breast cancer cases with somatic mutations in p53. However, different studies have produced widely differing RH estimates, ranging from no risk (RH = 1) to a relative hazard of 23, and not all of these results have been statistically significant. We have therefore reviewed all the published studies that have investigated the association between somatic mutations in the p53 gene and breast cancer prognosis and used standard techniques of meta-analysis to combine the results of these studies to produce a more precise estimate of the prognostic significance of p53 mutations. Eleven studies investigated overall survival in a total of 2319 unselected cases. The RH estimates from these ranged from 1 to 23.4 with a combined RH estimate of 2.0 (confidence interval 1.7–2.5). Three studies investigated the role of p53 in node-negative patients and in these, the combined estimate of RH was 1.7 (1.2–2.3). For three studies of node-positive breast cancer the combined risk estimate was 2.6 (1.7–3.9). The inclusion of p53 mutation screening in large breast cancer clinical trials seems warranted in the light of these results. Analysis of large numbers of cases matched for stage and therapy will allow definitive clarification of the value of p53 mutational status in prognostication, and possibly choice of therapy. © 1999 Cancer Research Campaign

Keywords: p53, breast cancer, prognosis

Full Text

The Full Text of this article is available as a PDF (78K).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Aas T, Børresen AL, Geisler S, Smith-Sørensen B, Johnsen H, Varhaug JE, Akslen LA, Lønning PE. Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients. Nat Med. 1996 Jul;2(7):811–814. [PubMed]
  • Allred DC, Clark GM, Elledge R, Fuqua SA, Brown RW, Chamness GC, Osborne CK, McGuire WL. Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer. J Natl Cancer Inst. 1993 Feb 3;85(3):200–206. [PubMed]
  • Andersen TI, Holm R, Nesland JM, Heimdal KR, Ottestad L, Børresen AL. Prognostic significance of TP53 alterations in breast carcinoma. Br J Cancer. 1993 Sep;68(3):540–548. [PMC free article] [PubMed]
  • Barnes DM, Dublin EA, Fisher CJ, Levison DA, Millis RR. Immunohistochemical detection of p53 protein in mammary carcinoma: an important new independent indicator of prognosis? Hum Pathol. 1993 May;24(5):469–476. [PubMed]
  • Beck T, Weller EE, Weikel W, Brumm C, Wilkens C, Knapstein PG. Usefulness of immunohistochemical staining for p53 in the prognosis of breast carcinomas: correlations with established prognosis parameters and with the proliferation marker, MIB-1. Gynecol Oncol. 1995 Apr;57(1):96–104. [PubMed]
  • Bergh J, Norberg T, Sjögren S, Lindgren A, Holmberg L. Complete sequencing of the p53 gene provides prognostic information in breast cancer patients, particularly in relation to adjuvant systemic therapy and radiotherapy. Nat Med. 1995 Oct;1(10):1029–1034. [PubMed]
  • Berns EM, van Staveren IL, Look MP, Smid M, Klijn JG, Foekens JA. Mutations in residues of TP53 that directly contact DNA predict poor outcome in human primary breast cancer. Br J Cancer. 1998 Apr;77(7):1130–1136. [PMC free article] [PubMed]
  • Bianchi S, Calzolari A, Vezzosi V, Zampi G, Cardona G, Cataliotti L, Bonardi R, Ciatto S. Lack of prognostic value of p53 protein expression in node-negative breast cancer. Tumori. 1997 May-Jun;83(3):669–672. [PubMed]
  • Børresen AL, Andersen TI, Eyfjörd JE, Cornelis RS, Thorlacius S, Borg A, Johansson U, Theillet C, Scherneck S, Hartman S, et al. TP53 mutations and breast cancer prognosis: particularly poor survival rates for cases with mutations in the zinc-binding domains. Genes Chromosomes Cancer. 1995 Sep;14(1):71–75. [PubMed]
  • Caleffi M, Teague MW, Jensen RA, Vnencak-Jones CL, Dupont WD, Parl FF. p53 gene mutations and steroid receptor status in breast cancer. Clinicopathologic correlations and prognostic assessment. Cancer. 1994 Apr 15;73(8):2147–2156. [PubMed]
  • Egger M, Smith GD. Misleading meta-analysis. BMJ. 1995 Mar 25;310(6982):752–754. [PMC free article] [PubMed]
  • Elledge RM, Fuqua SA, Clark GM, Pujol P, Allred DC, McGuire WL. Prognostic significance of p53 gene alterations in node-negative breast cancer. Breast Cancer Res Treat. 1993;26(3):225–235. [PubMed]
  • Elledge RM, Clark GM, Fuqua SA, Yu YY, Allred DC. p53 protein accumulation detected by five different antibodies: relationship to prognosis and heat shock protein 70 in breast cancer. Cancer Res. 1994 Jul 15;54(14):3752–3757. [PubMed]
  • Falette N, Paperin MP, Treilleux I, Gratadour AC, Peloux N, Mignotte H, Tooke N, Löfman E, Inganäs M, Bremond A, et al. Prognostic value of P53 gene mutations in a large series of node-negative breast cancer patients. Cancer Res. 1998 Apr 1;58(7):1451–1455. [PubMed]
  • Göhring UJ, Scharl A, Heckel C, Ahr A, Crombach G. P53 protein in 204 patients with primary breast carcinoma--immunohistochemical detection and clinical value as a prognostic factor. Arch Gynecol Obstet. 1995;256(3):139–146. [PubMed]
  • Gretarsdottir S, Tryggvadottir L, Jonasson JG, Sigurdsson H, Olafsdottir K, Agnarsson BA, Ogmundsdottir H, Eyfjörd JE. TP53 mutation analyses on breast carcinomas: a study of paraffin-embedded archival material. Br J Cancer. 1996 Aug;74(4):555–561. [PMC free article] [PubMed]
  • Hartmann A, Blaszyk H, Kovach JS, Sommer SS. The molecular epidemiology of p53 gene mutations in human breast cancer. Trends Genet. 1997 Jan;13(1):27–33. [PubMed]
  • Iacopetta B, Grieu F, Powell B, Soong R, McCaul K, Seshadri R. Analysis of p53 gene mutation by polymerase chain reaction-single strand conformation polymorphism provides independent prognostic information in node-negative breast cancer. Clin Cancer Res. 1998 Jul;4(7):1597–1602. [PubMed]
  • Isola J, Visakorpi T, Holli K, Kallioniemi OP. Association of overexpression of tumor suppressor protein p53 with rapid cell proliferation and poor prognosis in node-negative breast cancer patients. J Natl Cancer Inst. 1992 Jul 15;84(14):1109–1114. [PubMed]
  • Jansson T, Inganäs M, Sjögren S, Norberg T, Lindgren A, Holmberg L, Bergh J. p53 Status predicts survival in breast cancer patients treated with or without postoperative radiotherapy: a novel hypothesis based on clinical findings. J Clin Oncol. 1995 Nov;13(11):2745–2751. [PubMed]
  • Kovach JS, Hartmann A, Blaszyk H, Cunningham J, Schaid D, Sommer SS. Mutation detection by highly sensitive methods indicates that p53 gene mutations in breast cancer can have important prognostic value. Proc Natl Acad Sci U S A. 1996 Feb 6;93(3):1093–1096. [PubMed]
  • Lane DP. Cancer. p53, guardian of the genome. Nature. 1992 Jul 2;358(6381):15–16. [PubMed]
  • Levesque MA, Katsaros D, Yu H, Giai M, Genta F, Roagna R, Ponzone R, Massobrio M, Sismondi P, Diamandis EP. Immunofluorometrically determined p53 accumulation as a prognostic indicator in Italian breast cancer patients. Int J Cancer. 1998 Apr 17;79(2):147–152. [PubMed]
  • Lipponen P, Ji H, Aaltomaa S, Syrjänen S, Syrjänen K. p53 protein expression in breast cancer as related to histopathological characteristics and prognosis. Int J Cancer. 1993 Aug 19;55(1):51–56. [PubMed]
  • Norberg T, Lennerstrand J, Inganäs M, Bergh J. Comparison between p53 protein measurements using the luminometric immunoassay and immunohistochemistry with detection of p53 gene mutations using cDNA sequencing in human breast tumors. Int J Cancer. 1998 Aug 21;79(4):376–383. [PubMed]
  • Riou G, Lê MG, Travagli JP, Levine AJ, Moll UM. Poor prognosis of p53 gene mutation and nuclear overexpression of p53 protein in inflammatory breast carcinoma. J Natl Cancer Inst. 1993 Nov 3;85(21):1765–1767. [PubMed]
  • Seshadri R, Leong AS, McCaul K, Firgaira FA, Setlur V, Horsfall DJ. Relationship between p53 gene abnormalities and other tumour characteristics in breast-cancer prognosis. Int J Cancer. 1996 Apr 22;69(2):135–141. [PubMed]
  • Shiao YH, Chen VW, Scheer WD, Wu XC, Correa P. Racial disparity in the association of p53 gene alterations with breast cancer survival. Cancer Res. 1995 Apr 1;55(7):1485–1490. [PubMed]
  • Silvestrini R, Benini E, Daidone MG, Veneroni S, Boracchi P, Cappelletti V, Di Fronzo G, Veronesi U. p53 as an independent prognostic marker in lymph node-negative breast cancer patients. J Natl Cancer Inst. 1993 Jun 16;85(12):965–970. [PubMed]
  • Soong R, Iacopetta BJ, Harvey JM, Sterrett GF, Dawkins HJ, Hahnel R, Robbins PD. Detection of p53 gene mutation by rapid PCR-SSCP and its association with poor survival in breast cancer. Int J Cancer. 1997 Dec 19;74(6):642–647. [PubMed]
  • Stenmark-Askmalm M, Stål O, Sullivan S, Ferraud L, Sun XF, Carstensen J, Nordenskjöld B. Cellular accumulation of p53 protein: an independent prognostic factor in stage II breast cancer. Eur J Cancer. 1994;30A(2):175–180. [PubMed]
  • Thor AD, Moore DH II, Edgerton SM, Kawasaki ES, Reihsaus E, Lynch HT, Marcus JN, Schwartz L, Chen LC, Mayall BH, et al. Accumulation of p53 tumor suppressor gene protein: an independent marker of prognosis in breast cancers. J Natl Cancer Inst. 1992 Jun 3;84(11):845–855. [PubMed]
  • Thorlacius S, Thorgilsson B, Björnsson J, Tryggvadottir L, Börresen AL, Ogmundsdottir HM, Eyfjörd JE. TP53 mutations and abnormal p53 protein staining in breast carcinomas related to prognosis. Eur J Cancer. 1995 Oct;31A(11):1856–1861. [PubMed]
  • Tsuda H, Sakamaki C, Tsugane S, Fukutomi T, Hirohashi S. A prospective study of the significance of gene and chromosome alterations as prognostic indicators of breast cancer patients with lymph node metastases. Breast Cancer Res Treat. 1998 Mar;48(1):21–32. [PubMed]
  • Valgardsdottir R, Tryggvadottir L, Steinarsdottir M, Olafsdottir K, Jonasdottir S, Jonasson JG, Ogmundsdottir HM, Eyfjörd JE. Genomic instability and poor prognosis associated with abnormal TP53 in breast carcinomas. Molecular and immunohistochemical analysis. APMIS. 1997 Feb;105(2):121–130. [PubMed]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK